cyrilzakka/clinical-trials huggingface dataset:
Acupoint Application in Patients With Stable Angina Pectoris (AASAP)

Hypothesis: acupoint application is effective for managing chronic stable angina pectoris. Aim: to evaluate the efficacy and safety of acupoint application on the specific acupoints for chronic stable angina pectoris. Design: A Randomized, Controlled,Double Blind trial. 200 participants will be included. Four arms: herbal medicine application on acupoint group , placebo application on acupoint group , herbal medicine application on non-acupoint group and placebo application on non-acupoint group.

Acupoint application with herbal medicine is a kind of external treatment of traditional Chinese medicine and has a long history in China, which is use herbal medicine made of plaster and stick to specific acupoints, using the double effects of acupoints and herb to treat disease. In China, acupoint application with herbal medicine has been used in clinical treatment of angina pectoris, but there is no convincing evidence for the efficacy of acupoint application for angina pectoris, due to low methodologic quality and small sample size. The investigators designed the Randomized, Controlled, Double Blind clinical trial to investigates the efficacy of acupoint application in treating angina pectoris, the purpose of this study is to provide the convincing evidence for acupoint application treatment of angina pectoris.

Eligibility Criteria:
Inclusion Criteria:

1.Meet the diagnostic criteria of American College of Cardiology(ACC)/American Heart Association (AHA) angina pectoris of coronary heart disease.

2.35 ≤ age ≤ 85 years, both male and female.

3.The onset of angina pectoris≥3 months, and the frequency of angina attack≥2 a week.

4.Patients signed the informed consent

Exclusion Criteria:

1. age≤35 or age≥85.
2. Pregnant women or women in lactation or women of child bearing potential plan to conceive in the recent six months.
3. history of diabetes.
4. Co-infection or bleeding, allergic.
5. Currently participating in other clinical trials
The "CAD-Man" EXTEND Study

CAD-Man Extend is the long-term follow-up (clinical, laboratory, and computed tomography (CT) imaging) of a single-center, randomized, controlled CAD-Man trial comparing a CT-first strategy with a direct- invasive coronary angiography (ICA) diagnostic and management strategy, in 329 patients clinically referred for ICA with atypical angina or chest pain.

Overall goal:

The extension of CAD-Man follow-up (clinical, laboratory, and CT imaging) to approximately 10 years will provide the opportunity to compare plaque burden with CT-guided management versus direct-ICA at long-term and other endpoints.

The CAD-Man (Coronary Artery Disease Management with Multislice Computed Tomography and Magnetic Resonance Imaging in Patients with Atypical Angina Pectoris) trial evaluated whether computed tomography (CT) or invasive coronary angiography (ICA) should be performed in patients clinically referred for coronary angiography with an intermediate probability of coronary artery disease. Patients with suspected CAD were randomized 1:1 ratio to CT, followed by ICA if positive for obstructive CAD, or to direct ICA. In both tests, obstructive CAD was defined as at least a 50% diameter stenosis in the left main coronary artery or at least a 70% diameter stenosis in other coronary arteries. Investigators and participants were blinded to randomization sequence but could not be blinded to the assigned group because of the apparent differences between CT and ICA. Independent investigators, who were blinded to the randomization group and were not part of the study team, anonymously assessed outcomes. Results on the comparative effectiveness of CT and ICA in preventing the primary outcome of major procedural complications within 48 hours of the last procedure and major adverse events (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) were published for a median follow-up of 3.3 years.

The primary results and additional subgroup analyses of the CAD-Man trial led to three new hypotheses that will be evaluated in the CAD-Man Extend study.

1. Main hypothesis:

   Whether CT-guided management of patients with atypical angina results in a reduction in coronary plaque burden (as determined by repeat CT scan) compared with direct-ICA management until 10 years.
2. Secondary hypothesis:

1. Whether clinical characteristics or blood levels and lipid-lowering medications have an impact on intraindividual progression of coronary plaques in patients in the CT group.

2. Whether primary CT examination in patients with atypical angina leads to a reduction in chronic impairment of renal function after 10-years compared with initial ICA examination.

Eligibility Criteria:
Inclusion Criteria:

* Patients with suspected CAD
* Patients with atypical angina
* Patients who have previously participated in the CAD-Man study and have not died at a median follow-up of 3.3 years.

Exclusion Criteria:

Exclusion criteria for additional CT scan:

* Pregnancy
* Any health condition that would cause concern that participation would not be in the best interest of health (eg, extensive comorbidities)
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis

This is a Phase 4 open label, non-interventional, multi-center study to evaluate the safety of Enbrel (etanercept) treatment in patients receiving etanercept 25mg sc twice weekly or 50mg of etanercept once weekly. The improvement of health-related quality of life will also be evaluated.

Patients already prescribed to receive etanercept for the first time for treatment of Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary of Product Characteristics (SmPC).

Patients have been recruited sequentially based on eligibility criteria up to the number limit assigned to each site.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older at time of consent
* Satisfies the 1987 ACR Revised Criteria for Rheumatoid Arthritis or has a diagnosis of ankylosing spondylitis or psoriatic arthritis, as determined by the doctor
* Provides informed consent
* Demonstrate a negative serum or urine pregnancy test prior to administration of etanercept. Sexually active women participating in the study must use a medically acceptable form of contraception.
* Patients already prescribed etanercept according to approved labelling

Exclusion Criteria:

* Has hypersensitivity to etanercept
* Has sepsis or risk of sepsis. Treatment with etanercept should not be initiated in patients with active infections (ie. hepatitis C, hepatitis B, active TBC)
* Is pregnant or breast-feeding
* Has significant concurrent medical diseases including, uncompensated congestive heart failure, myocardial infarction within 12 months, unstable angina pectoris, or history of human immunodeficiency virus (HIV) infection, immunodeficiency syndromes, or central nervous system (CNS) demyelinating events suggestive of multiple sclerosis
* Has a history of confirmed blood dyscrasias
* Received any live (attenuated) vaccines within 4 weeks of screening visit
Quantitative Computed Tomodensitometry in Patients With Cystic Fibrosis

The purpose of this study is to conduct a comparative study for the study of bone mineralization evaluated with Quantitative computed tomodensitometry (QCT) compared to the reference technique, Dual-emission X-ray absorptiometry (DXA).

Patients with cystic fibrosis can have a deficit in bone mineralization. This is particularly well described in adults. However, in the pediatric population the results are more heterogeneous. The evaluation is hindered by difficulties in standardization of DXA interpretation.

This measurement depends from the mass and size of the bone as well as the mass of soft tissue covering the bone area. These two characteristics, intrinsic to the measurement, pose a significant problem of interpretations in children because a change in bone density may reflect both a change in bone mineral content or changes related to growth, for example, the increase in bone size or volume of soft tissue covering the bone of interest.

Quantitative computed tomography (QCT) provides a direct measure of bone mineralization densitometry volume. It quantifies bone mineral content in relation to the volume of the bone, in reference to an external phantom. This method therefore overcomes the size size.

This technique can be considered without an additional radiation exposure to patients during a lung CT because it is usual that lumbar vertebrae are included in the measurement window because of pulmonary hyperinflation. This exam would be ideal for patients with Cystic fibrosis.

All patients have these two evaluations during their routine management. This study compare study on the bone mineralization evaluated by (QCT) compared to the reference technique by (DXA) for the patient affected by cystic fibrosis for each patient.

Eligibility Criteria:
Inclusion Criteria:

* Patients affected by cystic fibrosis
* Aged over 5 years
* Patients whose clinical condition warrants an indication of chest CT in relation to the criteria of the french consensus conference on Cystic fibrosis in May 2002 (Palace of the Luxembourg).
* Patients whose clinical condition warrants an indication of DXA examination in accordance with French recommendations (Consensus of the Working Group "bone mineralization and cystic fibrosis" In children, the examination is recommended for ages 8 every 2 years if the Z-score is greater than - 1, every year if the Z-score is less than - 1.. In adults, the exam is recommended every 5 years if the T-score is greater than\> - 1, every 2 years if it is between -1 and - 2; annually if less than - 2.)
* Patient does not exhibit a phase of bronchial exacerbation
* Collection of non-opposition of the patient
* Patient affiliated to social security

Exclusion Criteria:

* Patient transplanted
* Patient with an infective exacerbation phase
Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.

Estrogen (EST) may have significant benefits in preserving cognitive functioning in normal aging after menopause and in decreasing the incidence of Alzheimer's disease (AD). On a molecular level, EST has effects on a variety of cholinergic neuronal and receptor-mediated mechanisms that may be responsible for these beneficial effects. These neurons have critical relevance for the development of age-related cognitive changes and dementing disorders. However, little is known about the clinical relevance of EST-cholinergic interactions, either in normal aging or in AD.

The primary goal of this study is to test the hypothesis that three months of administration of EST to 1) normal post-menopausal women, and 2) female patients with mild-moderate AD who are concurrently treated with anticholinesterase therapy (donepezil), will positively change or blunt the negative and behavioral effects of drugs that block central cholinergic receptors (both muscarinic and nicotinic). Participants will be blindly placed on EST or placebo for three months each. After each three month period, they will be cognitively assessed after receiving single doses of the cholinergic antagonists scopolamine and mecamylamine. These results will have direct implications for the use of EST in post-menopausal women as well as interactive treatment with cholinergic drugs for AD. Researchers plan to recruit a total of 45 women (30 healthy, and 15 patients with AD).

NOTE: This study is only recruiting participants with Alzheimer's Disease at this time.

Eligibility Criteria:
Inclusion Criteria:

* Normal volunteers and women with mild Alzheimer's disease:
* Non-smoker
* No use of Hormone Replacement Therapy for at least one year
* No menses for at least one year
* Normal mammogram within the last year
* minimum age is 45 for patients with Alzheimer's disease; 50 for normal volunteers
* Maximum age is 85 for patients with Alzheimer's disease; there is no maximum age for normal volunteers.

Exclusion Criteria:

* Women who are currently taking estrogen therapy.
* Women who are smokers.
* Women who have had breast cancer.
Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism

Based on the evidence that periostin is specifically involved in intra-cortical remodeling control, our working hypothesis is that assessment of its concentration in the serum would be helpful in identifying patients with severe cortical porosity, a critical parameter in bone fragility. Periostin expression by osteoblasts and osteocytes is part of the bone cortical response to anabolic stimuli such as mechanical strain or intermittent increase in parathyroid hormone. However, it remains unknown whether this expression may participate as well to mechanisms that will lead to exaggerated intra-cortical remodeling and subsequent bone loss.

In rare clinical situations in which trans-iliac bone biopsies will be necessary to better understand their bone status in addition to densitometry and biological bone markers assessment, specific analyses using immune-staining techniques will be performed on the bone sample. Data from routine follow-up every six months will be also collected in this specific sub-group.

High resolution peripheral quantitative computerized tomography (HR-pQCT) gives the opportunity of performing a virtual bone biopsy providing information on trabecular and cortical microarchitecture in vivo. These microarchitectural parameters allow a more accurate evaluation of the alteration of the bone structure and therefore of the fracture risk as compared to current tools used in clinical practice such as densitometry. However, the availability of such HRpQCT facilities is limited and there is on-going development on the best way of measuring porosity for example. The definition of a biological profile including key proteins such as periostin and sclerostin involved in porosity mechanisms is therefore of great interest. A better understanding of the relationship between bone matrix components and parathyroid hormone effects also appears as critical. Follow-up of routine evaluation parameters reflecting bone status in a subgroup of specific patients could also provide new and additional information.


Eligibility Criteria:
Inclusion Criteria:

* Hyperparathyroidism defined by a parathyroid hormone serum level above 65 ng/ml, secondary to Chronic Kidney Disease (CKD) ou vitamin D deficiency

Exclusion Criteria:

* Concurrent bone disease (such as Paget's disease, osteomalacia),
* Other endocrinopathy having an impact on bone metabolism (such as Cushing, hyperthyroidism, severe hypogonadism (except menopause)),
* Current or previous bisphosphonate treatment.
* Transplantation
* parathyroidectomy
* Life expectancy less than 3 months.
* Lack of study understanding.
* Lack of agreement.
* Under legal control.
Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits

Epilepsy is a frequent neurological disease in childhood, characterized by recurrent seizures and sometimes with major effects on social, behavioral and cognitive development. Childhood focal epilepsies particularly are age-related diseases mainly occurring during developmental critical period. A complex interplay between brain development and maturation processes and susceptibility genes may contribute to the development of various childhood epileptic syndromes associated with language and cognitive deficits. Indeed, the Landau-Kleffner syndrome (LKS), the continuous spike-and-waves during sleep syndrome (CSWS), and the benign childhood epilepsy with centrotemporal spikes (BCECTS) or benign rolandic epilepsy, are different syndromes that are considered as part of a single continuous spectrum of disorders. While genetic component in those three syndromes remains elusive, novel and high throughput genome analyzes could bring interesting insights into the possible genetic defects and pathophysiological mechanisms underlying and linking the various disorders associating epilepsy with speech and cognitive impairments.


Eligibility Criteria:
Inclusion Criteria:

* iodiopathic focal epilepsy with cognitif deficit

Exclusion Criteria:

* medical history of status epilepticus
Assessing Continuous Glucose Monitor Use in Underserved Primary Care Patients

The goal of this clinical trial is to evaluate the perceived and experienced benefits and barriers of Continuous Glucose Monitor (CGM) use and identify outcomes associated with CGM use relative to usual care with self-monitoring of blood glucose in an underserved patient population with type 2 diabetes.

The goal of this clinical trial is to evaluate the perceived and experienced benefits and barriers of CGM use and identify outcomes associated with CGM use relative to usual care with self-monitoring of blood glucose in an underserved patient population with type 2 diabetes. The main questions it aims to answer are:

* What are the perceived and experienced benefits of CGM use in an underserved patient population with type 2 diabetes?
* What differences are there in glucose monitoring frequency and glucose control between CGM and traditional glucometer testing in an underserved patient population with type 2 diabetes?

Participants will:

* Complete a baseline and final survey evaluating perceived/expected benefits or barriers to CGM use
* Be assigned to a CGM or usual care (traditional glucometer) arm for 6 months within an interprofessional primary care setting
* Complete laboratory testing at regular intervals that don't differ from usual diabetes care

Researchers will compare the CGM group to the traditional glucometer group to see if there are differences between (1) perceived/experienced benefits or barriers to the use of these devices, (2) glycemic clinical outcomes (hemoglobin A1c, hypoglycemia, hyperglycemia), and (3) glycemic measurement frequency.

Eligibility Criteria:
Inclusion Criteria:

* Type 2 diabetes
* A1c \>9% at recruitment • On/initiating insulin or on two or more diabetes medications

Exclusion Criteria:

* Current use of an insulin pump
* On dialysis
* Pregnant
* With an implanted medical device (e.g., pace-maker, defibrillator)
* Intellectual or physical disabilities (i.e., cognitive or physical) that may interfere with the patient's ability to properly use the CGM
* Language difficulties (must understand and be able to read English)
Kavalactones on Sleep and Cortisol in Healthy Special Forces Trainees

This research study is being done to better understand the effects of kava supplementation on sleep quality and salivary cortisol in the context of the acute physical and psychological stress of military special forces preparation training. Kava is a botanical dietary supplement derived from the plant Piper methysticum. Cortisol is a hormone associated with stress.

Acute physical and behavioral stress can interfere with sleep quality and cause cortisol to increase. This can have a negative impact on quality of life and the ability to perform optimally.

Kava, derived from the rootstumps of the Piper methysticum plant, has been utilized traditionally, socially, and for its calmative properties by the peoples of Oceania for millennia. Kava has been available as a dietary supplement for decades.

Participants in this placebo-controlled cross-over study will be enrolled concurrently with a special operations prep class during which they will be experiencing significant physical and mental stressors. Participants will be divided into two arms - one taking kava and the other taking placebo for the first two-week phase of the study. Following a washout and cross-over, participants will switch what they are taking for the second two-week phase.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Provides consent to participate in the study
* Understands and agrees to follow all study procedures and limitations

Exclusion Criteria:

* Female
* Use of kava within the past 8 weeks
* Use of over the counter or prescription sleep aids including dietary supplements within the past 8 weeks
* Use of acetaminophen that cannot be discontinued or replaced with an NSAID during the study
* Known liver disease or dysfunction
* Known kidney disease or dysfunction
* Any prior adverse reaction or known sensitivity or allergy to kava or related botanicals (peppers)
* Recent history of clinical depression or anxiety diagnosis
Effect of Auricular Acupressure on Sleep Quality in Nurses

The purpose of this study is to explore Effect of Auricular Acupressure on Improving Sleep Quality in Nurses. Adopting a quasi-experimental research design and convenience sampling, nursing staff from a northern medical center who scored 5 or higher on the Pittsburgh Sleep Quality Scale were selected as research subjects. Eligible participants were assigned to either the experimental group (auricular acupoint sticking) or the control group (no intervention).Pittsburgh Sleep Quality Scale were measured on the day of application, as well as during the fourth and eighth weeks. The collected data were analyzed using SPSS 29.0 for Windows.

Background: Nursing staff face various pressures, shift systems, household responsibilities, and hormonal changes within the medical environment. They frequently experience issues such as sleep deprivation and inadequate rest, which can result in diminished work performance and increased fatigue. This, in turn, indirectly impacts the quality of care provided and heightens the risk to patient safety. Aim: Effect of Auricular Acupressure on Improving Sleep Quality in Nurses Methods: Adopting a quasi-experimental research design and convenience sampling, nursing staff from a northern medical center who scored 5 or higher on the Pittsburgh Sleep Quality Scale were selected as research subjects. Eligible participants were assigned to either the experimental group (auricular acupoint sticking) or the control group (no intervention). In the experimental group, the Shenmen point (MA-TF1) and Xin point (Xin MA) on both ears were treated with Wangbuliuxing seeds. Initially, the seeds were applied to the left ear for seven days, after which they were switched to the corresponding acupoints on the right ear. Following application, the seeds were pressed daily, once after each meal, with each acupoint being stimulated for 1 minute.Pittsburgh Sleep Quality Scale were measured on the day of application, as well as during the fourth and eighth weeks. The collected data were analyzed using SPSS 29.0 for Windows. Statistical analyses included percentages, means, chi-square tests, paired t-tests, independent t-tests, and generalized estimating equations to compare differences in sleep quality between the two groups.

Eligibility Criteria:
Inclusion Criteria:

1. Aged 18
2. Nurses whose score on Pittsburgh Scale is greater than 5.
3. Those who are conscious, can communicate in Mandarin and Taiwanese, and answer the questionnaires in writing or orally, agree to participate in this study and sign the subject consent form.

Exclusion Criteria:

1. People with mental illness
2. infection or skin breakouts around the ears